Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$34.88 - $43.22 $3.69 Million - $4.57 Million
105,840 New
105,840 $4 Billion
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $3.71 Million - $5.17 Million
109,801 New
109,801 $4.65 Million
Q3 2022

Nov 14, 2022

SELL
$31.52 - $373.61 $270,693 - $3.21 Million
-8,588 Reduced 6.33%
127,045 $4.08 Million
Q2 2022

Aug 15, 2022

BUY
$26.83 - $38.57 $504,028 - $724,576
18,786 Added 16.08%
135,633 $4.41 Million
Q1 2022

May 11, 2022

BUY
$30.95 - $39.68 $144,381 - $185,107
4,665 Added 4.16%
116,847 $4.23 Million
Q4 2021

Feb 11, 2022

BUY
$35.87 - $47.12 $53,231 - $69,926
1,484 Added 1.34%
112,182 $4.44 Million
Q3 2021

Nov 12, 2021

BUY
$41.55 - $48.72 $1.46 Million - $1.71 Million
35,195 Added 46.61%
110,698 $4.84 Million
Q2 2021

Aug 11, 2021

SELL
$32.88 - $44.57 $20,352 - $27,588
-619 Reduced 0.81%
75,503 $3.08 Million
Q1 2021

May 13, 2021

SELL
$30.92 - $44.4 $68,425 - $98,257
-2,213 Reduced 2.83%
76,122 $2.5 Million
Q4 2020

Feb 09, 2021

BUY
$33.66 - $40.76 $3,433 - $4,157
102 Added 0.13%
78,335 $3.19 Million
Q3 2020

Nov 12, 2020

SELL
$33.07 - $38.68 $413,441 - $483,577
-12,502 Reduced 13.78%
78,233 $2.86 Million
Q2 2020

Aug 12, 2020

BUY
$20.05 - $33.89 $121,883 - $206,017
6,079 Added 7.18%
90,735 $3.08 Million
Q1 2020

May 06, 2020

SELL
$17.15 - $25.22 $97,703 - $143,678
-5,697 Reduced 6.31%
84,656 $1.79 Million
Q4 2019

Feb 14, 2020

SELL
$18.88 - $24.14 $16,538 - $21,146
-876 Reduced 0.96%
90,353 $2.02 Million
Q3 2019

Nov 07, 2019

BUY
$18.0 - $21.38 $1.64 Million - $1.95 Million
91,229 New
91,229 $1.85 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.8B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.